Background

CD47 is a widely expressed cellular receptor well known for its immunoregulatory functions. By interacting with its ligands, including thrombospondin-1 (TSP-1), signal regulatory protein α (SIRPα), integrins, and SH2-domain bearing protein tyrosine phosphatase substrate-1 (SHPS-1), it modulates cellular phagocytosis by macrophages, transmigration of neutrophils and activation of dendritic cells, T cells and B cells. Ample studies have shown that various types of cancer express high levels of CD47 to escape from the immune system. Based on this observation, CD47 is currently considered as a prominent target in cancer therapy.

Conclusions

Here, we review the role of CD47 in the maintenance of immune system homeostasis. We also depict three emerging CD47-targeting strategies for cancer therapy, including the use of mimicry peptides, antibodies, and gene silencing strategies. Among these approaches, the most advanced one is the use of anti-CD47 antibodies, which enhances cancer cell phagocytosis via inhibition of the CD47-SIRPα axis. These antibodies can also achieve higher anti-cancer efficacies when combined with chemotherapy and immunotherapy and hold promise for improving the survival of patients with cancer.

中文翻译：

---

CD47：在免疫系统中的作用及其在癌症治疗中的应用。

背景

CD47是一种广泛表达的细胞受体，以其免疫调节功能而闻名。通过与它的配体相互作用，包括血小板反应蛋白1（TSP-1），信号调节蛋白α（SIRPα），整联蛋白和带有SH2结构域的酪氨酸磷酸酶底物1（SHPS-1），它可以通过巨噬细胞调节细胞吞噬作用，中性粒细胞的迁移以及树突状细胞，T细胞和B细胞的活化。大量的研究表明，各种类型的癌症都表达高水平的CD47逃离免疫系统。基于此观察，CD47目前被认为是癌症治疗中的重要靶标。

结论

在这里，我们回顾CD47在维持免疫系统稳态中的作用。我们还描述了用于癌症治疗的三种新兴CD47靶向策略，包括模拟肽，抗体和基因沉默策略的使用。在这些方法中，最先进的方法是使用抗CD47抗体，该抗体通过抑制CD47-SIRPα轴来增强癌细胞的吞噬作用。当与化学疗法和免疫疗法结合时，这些抗体还可以实现更高的抗癌功效，并有望改善癌症患者的生存。